Regulatory advice on evaluation of the proarrhythmic potential of drugs
Norman Stockbridge(United States Food and Drug Administration), Douglas C. Throckmorton(United States Food and Drug Administration)
Cited by 15
Related Papers
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
|Circulation|2018|712
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
Clinical Outcome Endpoints in Heart Failure Trials: A European Society of Cardiology Heart Failure Association Consensus Document
|European Journal of Heart Failure|2013|233
PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products
|Kidney International|1995|174